ArticleCellular oncology (Dordrecht, Netherlands)2022

BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer.

Francesca De Santis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.